Theravia

Executive Summary

Theravia is a private French pharmaceutical laboratory formed in 2011 through the merger of Addmedica and CTRS, specializing in rare and neglected diseases. With a compact team of 11-50 employees, the company focuses on addressing unmet medical needs in challenging conditions, leveraging orphan drug designations and other regulatory incentives. While Theravia maintains a low public profile, its targeted pipeline in niche therapeutic areas positions it for potential value inflection points, including regulatory milestones and strategic partnerships. The company operates in the generic drugs category but its emphasis on rare diseases suggests a mix of branded and specialty products.

Upcoming Catalysts (preview)

• Q3 2026Receipt of Orphan Drug Designation for a Lead Rare Disease Candidate70% success
• Q4 2026Announcement of a Commercial Partnership for Key European Markets50% success
• Q1 2027Interim Data from a Phase 2 Trial in Neglected Disease40% success